Su-jie Zhu

Qingdao, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification.

Dimeric natural product panepocyclinol A inhibits STAT3 via di-covalent modification.

Journal: Acta pharmaceutica Sinica. B

Published: June 12, 2024

Adaptive best subset selection algorithm and genetic algorithm aided ensemble learning method identified a robust severity score of COVID-19 patients.

Adaptive best subset selection algorithm and genetic algorithm aided ensemble learning method identified a robust severity score of COVID-19 patients.

Journal: iMeta

Published: May 19, 2023

Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Journal: ACS medicinal chemistry letters

Published: October 10, 2021

A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.

A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.

Journal: EMBO molecular medicine

Published: March 19, 2021

Structural Basis of AZD9291 Selectivity for EGFR T790M.

Structural Basis of AZD9291 Selectivity for EGFR T790M.

Journal: Journal of medicinal chemistry

Published: July 17, 2020

Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S).

Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S).

Journal: Journal of medicinal chemistry

Published: July 13, 2019

Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.

Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.

Journal: ACS medicinal chemistry letters

Published: August 15, 2018

Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.

Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.

Journal: Biochemical and biophysical research communications

Published: May 17, 2018

Structural insights into drug development strategy targeting EGFR T790M/C797S.

Structural insights into drug development strategy targeting EGFR T790M/C797S.

Journal: Oncotarget

Published: July 12, 2017

Structural pharmacological studies on EGFR T790M/C797S.

Structural pharmacological studies on EGFR T790M/C797S.

Journal: Biochemical and biophysical research communications

Published: April 20, 2017

Structural basis of mutant-selectivity and drug-resistance related to CO-1686.

Structural basis of mutant-selectivity and drug-resistance related to CO-1686.

Journal: Oncotarget

Published: March 31, 2017

Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator.

Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator.

Journal: Cell

Published: April 02, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026